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Trudeau E1, Dias C1, Lambert T2, Chambost H3, Peynet J4,
Fressinaud E5, Guerois C6
1Mapi Values, LYON, France; 2CHU Bicetre, Kremlin Bicetre,
France; 3CHU Timone, Marseille, France; 4CTS, Le Chesnay,
France; 5CHU Hotel Dieu, Nantes, France; 6CHU Hopital
Trouseau,Tours, France
OBJECTIVES: To develop a haemophilia-speciﬁc ques-
tionnaire exploring Quality of Life (QoL) of four age
groups: adult (18–36 years), adolescent (12–17 years),
children (7–11 years), and young children (3–7 years).
METHODS: The questionnaire was developed in French
following a literature review and in depth interviews
among 3 men suffering from severe haemophilia, 3
mothers of haemophilia children and 5 clinical experts (2
haematologists, 1 paediatrician, 1 nurse and 1 psycholo-
gist). RESULTS: An adult version of the questionnaire
was ﬁrst developed using patient’s verbatim. It contained
89 questions and covered the following 7 quality of life
domains: Haemophilia and its treatment, Daily life,
School, Professional life, Leisure activities and sports,
Family and friends, Emotional well-being and Future per-
spective. Three other versions of the questionnaire were
developed simultaneously based on the adult version: 77-
item adolescent questionnaire, 22-item children question-
naire and 45-item parent of children questionnaire. All
domains were covered in all versions, except for profes-
sional life. All age-group versions are self-administered
including children from 7 to 11 years old. In addition
parents ﬁll in the 45-item questionnaire for 3–11 age-
groups. Content validity of the questionnaires was sub-
mitted to a Scientiﬁc committee for revision and approval.
The questionnaire is currently being evaluated in a French
cross-sectional pilot study including 54 severe
haemophilia A patients. The objectives are to describe
QoL items among different age groups, assess the accept-
ability and the relevance of the questionnaire and perform
item-reduction. CONCLUSION: The reduced QoL ques-
tionnaire will be available to the scientiﬁc community
soon for further psychometric analysis. The Haemophilia
age-group QoL questionnaire offers the unique opportu-
nity to assess haemophilia patients’ QoL from early child-
hood to adult life. This study was supported by a grant
from Baxter.
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SYSTEMS LEAD TO COST SAVINGS IN THE UK
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OBJECTIVES: Human growth hormone (hGH) treat-
ment is potentially expensive, and improvements in
dosing accuracy through more precise delivery systems
may lead to reductions in costs due to a minimization of
wastage. To test this hypothesis, we assessed potential
cost savings in the treatment of childhood growth
hormone deﬁciency (GHD) and small for gestational age
(SGA) due to differences in the precision of dosing of
hGH delivery systems. METHODS: Three delivery sys-
tems with differing dose increment size were compared
(Norditropin NordiFlex with dosing increments of 
0.025mg versus Genotropin Pen and Humatrope Pen
both with 0.1mg dosing increments). The recommended
daily dose of hGH for each indication for 1kg body
weight intervals was combined with costs per mg hGH
(taken from published UK sources) to calculate annual
costs of hGH treatment for GHD and SGA patients. The
calculations were based on the assumption that patients
received the required daily dose as a minimum or the
lowest possible injectable dose above the required daily
dose. RESULTS: Due to more precise incremental dose
delivery, using Norditropin NordiFlex versus the two
other comparators was found to save an average of 6.2%
of the annual hGH dose. This translated into annual drug
cost savings of £254.32 and £179.53 per patient com-
pared to Genotropin Pen and Humatrope Pen respec-
tively. In patients with lower body weight, where smaller
dosing increments were more critical to accurate dosing,
even greater savings of up to 10% were found. These
results were robust in all body weight categories and in
both GHD and SGA. CONCLUSIONS: More precise
dosing with the Norditropin NordiFlex delivery system
compared to Genotropin Pen and Humatrope Pen led to
cost savings in the UK setting in patients with GHD and
SGA.
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Generic measures of health-related quality of life
(HrQoL) are designed for use in a wide range of thera-
peutic settings whereas condition-speciﬁc measures have
a much narrower focus. The performance of the latter in
general population settings is largely unknown. OBJEC-
TIVES: 1) To demonstrate the differential health status of
individuals with a speciﬁc condition and hence its health
burden; 2) to test the discriminatory power of a condi-
tion-speciﬁc measure of HrQoL and; 3) to develop nor-
mative reference values of QoL-AGHDA. METHODS:
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QoL-AGHDA is designed for use in patients with growth
hormone deﬁciency (GHD). It comprises a 25-item ques-
tionnaire that elicits yes/no responses that are used to
compute an aggregate summary index. A high QoL-
AGHDA score denotes poor HrQoL. The survey sample
consisted of 1000 individuals randomly selected from the
UK Population Preference Panel. Individuals were sent a
modiﬁed form of the QoL-AGHDA (including EQ-5D).
The population data were compared with corresponding
data on patients in UK KIMS (Pﬁzer International Meta-
bolic Database). RESULTS: Completed survey forms
were received from 882 individuals (57% female, median
age 55, range 18–90). The mean QoL-AGHDA scores in
the general population was 6.78 (sd = 5.85, n = 868). The
corresponding mean for patients was 14.71 (sd = 5.58, 
n = 841). There was a high degree of correlation with EQ-
5D. Comparison with corresponding data for patients
diagnosed and/or treated for GHD indicate signiﬁcant 
differential patterns of response, with much higher 
QoL-AGHDA scores commensurate with lower levels 
of HrQoL in this group. CONCLUSIONS: This study
reports for the ﬁrst time on the use of QoL-AGHDA in
a UK general population setting. It provides important
evidence on the performance of this condition-speciﬁc
measure as well as calibrating normative reference values.
Additionally it conﬁrmed the discriminant validity of the
measure and demonstrated the health burden of patients
with GHD.
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OBJECTIVES: To analyze how newly HIV+ diagnosed
patients are managed in 3 French HIV Public Hospitals.
METHODS: STAR is an observational study designed to
prospectively collect electronic data on immunological
and virological status, anti-retroviral therapy (ART) and
medical cost of HIV+ patients. Newly diagnosed (de
novo) patients are exhaustively included in the cohort
since February 2002 in order to identify therapeutic
strategies in the setting of clinical practice. RESULTS: At
the end of March 2003, a total of 328 de novo patients
(65% male) were included, of mean age 36.8 ± 10.5 years,
mainly infected through sexual contacts (49% heterosex-
ual and 27% homosexual). At the time of HIV diagno-
sis, mean CD4 counts and viral load were respectively
368 ± 278 /mm3 and 111,947 ± 164,986 copies/ml. Fifty-
ﬁve patients (17%) had already clinical AIDS status 
and the mean time from seropositivity was 248 ± 104
days. In March 03, 59.5% of patients were without ART
(among whom 94.4% were totally ART-naïve), 36%
were treated with a combination of 3 anti-retrovirals and
4% with 4 anti-HIV drugs. The most frequent combina-
tions were 3 NRTIs (38%) and 2 NRTIs + 1 boosted Pro-
tease Inhibitor (29%). The mean time between HIV
diagnosis and initiation of ART was 66 ± 72 days and the
mean duration of follow-up of non-treated patients was
237 ± 107 days. During the observation period, 29.2%
of treated patients had their treatment changed at least
once, mainly because of drug-related intolerance. A total
of 38% remained under the same ARV combination but
changed at least one molecule. CONCLUSION: These
ﬁndings obtained after 14 months showed signiﬁcant
trends in the management of newly HIV+ diagnosed
patients with a large majority of patients without ART, a
high diversity of initial ART regimens and a high fre-
quency of early interruption.
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ASSOCIATION BETWEEN UNSUCCESSFUL
INITIAL EMPIRIC ANTIBIOTIC THERAPY AND
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INFECTIONS IN SPAIN
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OBJECTIVES: Assess the association between unsuccess-
ful initial empiric antibiotic therapy and Health care
resource use among patients undergoing surgery for com-
munity-acquired intra-abdominal infections (CIAI) in
Spain. METHODS: Records of patients who underwent
surgery for CIAI from October 1998 to August 2002 in
hospitals in Spain were reviewed. Empiric antibiotic
therapy was classiﬁed as successful if CIAI was resolved
with initial therapy or with decrease from initial therapy;
and as unsuccessful if IAI was resolved with additional
therapy, additional surgery, died in hospital, or re-
hospitalized within 30 days of discharge. Health care
resource use was measured by hospital length of stay in
days (LOS) and days on IV antibiotic therapy and were
compared between patients with successful and unsuc-
cessful therapy using the non-parametric Kruskal-Walis
test. Least square regression analyses with log transfor-
mation of the outcome variables were performed to assess
associations between unsuccessful IEAT and Health care
resource use measures, after adjusting for patients’ demo-
graphic and co-morbid characteristics as well as site/type
of infection. Four hundred twenty-ﬁve patients were
included. RESULTS: Mean (SD) age was 53.2 (20.7);
40.5% female. 315 (74.1%) patients had successful
therapy (resolved with initial or with decrease from initial
